Does Scripps Health Cover Eliquis?

How Scripps Health Insurance Plans Handle Eliquis

Scripps Health operates as a nonprofit integrated health system based in San Diego, and it offers employer-sponsored insurance through Scripps Health Plan. Coverage for Eliquis (apixaban) depends on which specific plan a member holds. In most commercial Scripps plans, apixaban appears on the formulary as a Tier 3 preferred brand medication, which means the drug is covered but carries a higher copay than generic alternatives like warfarin.

The distinction matters financially. A Tier 1 generic drug on a Scripps plan might cost $10 to $15 per fill. Eliquis on Tier 3 runs $35 to $90 depending on the plan year and whether the member has met their annual deductible. Members enrolled through Scripps Medicare Advantage products may see different cost-sharing structures governed by CMS formulary rules. The FDA's original approval of apixaban in December 2012 covered stroke prevention in nonvalvular atrial fibrillation, and subsequent label expansions for venous thromboembolism broadened the patient population eligible for coverage.

If your Scripps plan does not list apixaban on its formulary, that does not necessarily mean a permanent denial. Your prescribing physician can submit a prior authorization request documenting medical necessity, and Scripps plans are required to process these within 72 hours for urgent requests under California law.

Why Eliquis Is Prescribed Over Warfarin

Apixaban earned its clinical reputation in the ARISTOTLE trial (N=18,201), which demonstrated a 21% relative risk reduction in stroke or systemic embolism compared to warfarin (1.27% vs. 1.60% per year, P<0.001), along with a 31% reduction in major bleeding [1]. That bleeding advantage is the primary reason many cardiologists now prescribe apixaban as a first-line anticoagulant for atrial fibrillation.

The trial also showed a statistically significant reduction in all-cause mortality (3.52% vs. 3.94%, P=0.047) [1]. Dr. Christopher Granger, the ARISTOTLE principal investigator from Duke University, stated: "Apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality." These results changed practice guidelines worldwide.

For DVT and pulmonary embolism treatment, the AMPLIFY trial (N=5,395) found apixaban noninferior to conventional enoxaparin-warfarin therapy for recurrent VTE while producing 69% less major bleeding (0.6% vs. 1.8%, P<0.001) [2]. The American College of Cardiology and the American Heart Association both include apixaban among recommended DOACs in their joint atrial fibrillation management guidelines [3].

These outcomes explain why insurers, including Scripps Health Plan, generally cover apixaban despite its higher cost compared to warfarin, which runs roughly $4 to $10 per month as a generic.

Understanding the Prior Authorization Process at Scripps

Many Scripps Health plans require prior authorization before filling an Eliquis prescription. This is standard across most commercial insurers for brand-name DOACs. The process typically works in three steps.

First, your physician submits a prior authorization form to Scripps Health Plan documenting the clinical indication (atrial fibrillation, VTE, or surgical prophylaxis), relevant lab values such as CrCl for renal dosing, and any contraindications to alternative anticoagulants. Second, the plan's pharmacy benefit team reviews the request against formulary criteria. Third, a determination letter arrives within 72 hours for urgent requests or up to 14 days for standard requests.

Common reasons for initial denial include missing documentation of a CHA2DS2-VASc score for atrial fibrillation patients, failure to document why warfarin is not appropriate, or an incomplete medication history. If denied, California's Department of Managed Health Care requires that Scripps plans provide a clear written explanation and instructions for appeal [4]. The internal appeal process allows 30 days for submission and must be resolved within 30 days after that.

A practical approach: ask your Scripps cardiologist or primary care provider to include the CHA2DS2-VASc score, bleeding risk (HAS-BLED score), estimated CrCl, and a brief note on warfarin unsuitability in the initial prior authorization submission. Providing all four data points on the first request reduces denial rates significantly.

What Eliquis Costs on a Scripps Health Plan

The retail price of Eliquis without insurance averages $615 to $720 for a 30-day supply of the standard 5 mg twice-daily dose, according to FDA-reported pricing data. On a Scripps Health commercial plan, members typically pay one of the following amounts depending on their tier structure.

Tier 2 (preferred brand on select plans): $35 to $50 copay per 30-day fill. Tier 3 (nonpreferred brand): $60 to $90 copay per 30-day fill. High-deductible plans: full retail price until the deductible is met, then coinsurance of 20% to 30%.

For members on Scripps Medicare Advantage plans, Part D formulary rules apply. Eliquis often falls into Tier 4 (specialty) on Medicare Part D, with coinsurance of 25% to 33% during the initial coverage phase. Once a member enters the coverage gap, manufacturer discounts and the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective since 2025) can substantially reduce total costs [5].

Bristol-Myers Squibb offers a copay savings card for commercially insured patients that can reduce the out-of-pocket cost to as little as $10 per month. This card does not apply to government-funded plans (Medicare, Medicaid, Tricare). Eligible Scripps members with commercial coverage should ask their pharmacist about activating this card at the point of sale.

Scripps Health Formulary Alternatives to Eliquis

If Eliquis is denied or too expensive on your Scripps plan, several alternatives exist. Each carries different clinical trade-offs.

Warfarin remains the lowest-cost option at $4 to $10 per month but requires regular INR monitoring (typically every 2 to 4 weeks), interacts with many foods and drugs, and carries higher bleeding risk than apixaban based on the ARISTOTLE data [1]. Xarelto (rivarelbaan) is another DOAC that Scripps plans generally cover at a similar tier to Eliquis. The ROCKET AF trial (N=14,264) demonstrated noninferiority to warfarin for stroke prevention, though it did not show the same bleeding advantage that apixaban achieved [6].

Pradaxa (dabigatran) offers a third DOAC option. The RE-LY trial (N=18,113) showed that dabigatran 150 mg twice daily was superior to warfarin for stroke prevention but with similar rates of major bleeding [7]. One advantage of dabigatran: it has a specific reversal agent (idarucizumab) that is widely stocked in Scripps emergency departments.

Savaysa (edoxaban), the fourth available DOAC, is less commonly prescribed but sits on some Scripps formularies at a lower tier. The ENGAGE AF-TIMI 48 trial (N=21,105) demonstrated noninferiority to warfarin with lower bleeding rates for the 60 mg dose [8].

Your cardiologist can determine which DOAC best fits your clinical profile. Renal function, body weight, and concomitant medications all influence the choice. The 2023 ACC/AHA/ACCP/HRS Atrial Fibrillation Guideline recommends DOACs over warfarin for most patients with nonvalvular atrial fibrillation, with apixaban and dabigatran receiving the strongest evidence ratings [3].

How to Appeal a Scripps Health Denial for Eliquis

An initial denial is not the final word. Scripps Health Plan members have structured appeal rights under California insurance regulations.

Start with the internal appeal. Submit a written request within 30 days of the denial letter. Include updated clinical notes from your prescriber, the specific formulary exception criteria your case meets, and any new lab results (renal function panels, bleeding risk scores). Scripps must respond within 30 days for standard appeals or 72 hours for urgent/expedited appeals.

If the internal appeal fails, California members can file an Independent Medical Review (IMR) through the Department of Managed Health Care. The IMR process is free and uses external physician reviewers who are not employed by Scripps. According to DMHC data, approximately 60% of pharmaceutical IMR cases result in overturning the health plan's denial.

Dr. Mintu Turakhia, a Stanford electrophysiologist and anticoagulation researcher, has noted: "Access barriers to DOACs remain a significant contributor to suboptimal stroke prevention. The clinical evidence strongly favors these agents over warfarin for most patients, and appeal processes should reflect that evidence base."

For prescriptions needed urgently (active DVT, new atrial fibrillation diagnosis with high stroke risk), your physician can request an expedited review by calling the Scripps Health Plan pharmacy line directly and citing the 72-hour California urgent review mandate.

Patient Assistance Programs Beyond Insurance

Even with Scripps coverage, some patients face prohibitive costs. Several programs can help.

The Bristol-Myers Squibb/Pfizer Patient Assistance Foundation provides free Eliquis to uninsured or underinsured patients with household incomes below 300% of the federal poverty level. The application requires proof of income, a prescription, and a brief physician attestation.

For Medicare patients, Extra Help (Low-Income Subsidy) through CMS can reduce Part D copays to $0 to $11 per prescription for those who qualify. The Inflation Reduction Act provisions cap total Part D out-of-pocket spending at $2,000 annually, which benefits patients taking expensive brand-name medications like Eliquis [5].

San Diego County residents can also contact Scripps financial counselors at any Scripps hospital campus. These counselors can identify plan-specific discount programs, connect patients with manufacturer cards, and assist with Medi-Cal applications if income qualifies.

Pharmacy shopping matters too. A 90-day mail-order fill through the Scripps Health Plan preferred mail pharmacy often costs less per dose than three consecutive 30-day retail fills. Ask your plan about mail-order pricing before your next refill.

Renal Dosing and Coverage Implications

Eliquis dosing adjustments affect both clinical outcomes and insurance coverage. The standard dose is 5 mg twice daily, but patients meeting at least two of three criteria (age ≥80, body weight ≤60 kg, serum creatinine ≥1.5 mg/dL) require a reduced dose of 2.5 mg twice daily [9].

This dosing distinction matters for Scripps plan coverage because some prior authorization protocols require documentation of renal function before approval. A serum creatinine and estimated CrCl within the past 90 days is a common formulary requirement. The FDA prescribing information specifies that no dose adjustment is needed for mild-to-moderate renal impairment alone, but the combination criteria must be assessed [9].

For patients on hemodialysis, limited data exist. A pharmacokinetic study published in the American Journal of Kidney Diseases found that apixaban 5 mg twice daily in dialysis patients produced drug levels comparable to the general population [10]. The 2019 RENAL-AF pilot trial suggested similar safety to warfarin in this population, though the study was underpowered for efficacy conclusions. Scripps nephrologists may need to submit additional documentation for dialysis patients seeking Eliquis coverage.

Generic Apixaban: When Will It Lower Costs?

No FDA-approved generic apixaban is available as of May 2026. Bristol-Myers Squibb's composition-of-matter patent on apixaban was set to expire in 2026, but ongoing litigation with generic manufacturers has complicated the timeline.

Several companies, including Teva, Aurobindo, and Micro Labs, have filed Abbreviated New Drug Applications (ANDAs) with the FDA for generic apixaban [11]. Patent settlement agreements between BMS/Pfizer and certain generic firms may allow limited generic entry before full patent expiration.

When generics do arrive, Scripps Health Plan formularies will likely shift apixaban to a lower tier with reduced copays, as happened with other drugs following generic entry. Until then, the manufacturer copay card and patient assistance programs remain the primary tools for cost reduction on Scripps plans.

Patients should ask their Scripps pharmacist or plan representative annually about formulary changes during open enrollment. Tier placements can shift from year to year, and a drug that was Tier 3 in one plan year might move to Tier 2 if the plan negotiates better pricing.